Balanced news tone
News Sentiment
302440 sentiment intelligence
SK bioscience Co.,Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
7 relevant articles
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-2.8% over one week, -6.5% over four weeks, trend inactive, and below fair value.
SK Bioscience stock trades steady as vaccine revenue supports margins
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
83/100 classification
One-week reaction
-2.8%
Price reacting lower
Trend fit
Trend inactive
-6.5% over four weeks
Fair value
-31.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
5
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
ad-hoc-news.de
Direct company coverage
SK Bioscience stock trades steady as vaccine revenue supports margins
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 19:45
- Source
- ad-hoc-news.de
ad-hoc-news.de
Direct company coverage
Sky Cell Flu from SK Bioscience - Korea’s leading cell-based influenza shot
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 22:52
- Source
- ad-hoc-news.de
ad-hoc-news.de
Direct company coverage
SK Bioscience outlines vaccine growth strategy as biotech interest stays high
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Jul 2026 17:56
- Source
- ad-hoc-news.de
ad-hoc-news.de
Direct company coverage
SK Bioscience outlines long-term vaccine strategy as a Korean biotech player builds global partnersh
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 11:19
- Source
- ad-hoc-news.de
Reuters
Direct company coverage
Vaccine developer SK Bioscience to raise $1.3 bln in S.Korea's largest IPO since 2017
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Mar 2021 08:00
- Source
- Reuters
KED Global
Direct company coverage
SK Bioscience’s $1.3 bn IPO generates $10 mn in underwriting fees
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Mar 2021 08:00
- Source
- KED Global
KED Global
Direct company coverage
Controversy surrounds SK Bioscience’s $1 bn IPO valuation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Feb 2021 08:00
- Source
- KED Global